Magnetic nanoparticles for tumor imaging and therapy: a so-called theranostic system.
Magnetic nanoparticles for tumor imaging and therapy: a so-called theranostic system.
复制标题
DOI：
10.1007/s11095-013-0982-y
复制
发表时间：
2013-10
影响因子：
3.7
通讯作者：
Yang, Victor C.
中科院分区：
文献类型：
--
作者：
He, Huining;David, Allan;Chertok, Beata;Cole, Adam;Lee, Kyuri;Zhang, Jian;Wang, Jianxin;Huang, Yongzhuo;Yang, Victor C.
关键词：
在这篇综述中，我们讨论了通过建立基本原理来建立所谓的“治疗诊断”系统，包括使用：[1]基于磁性氧化铁纳米颗粒（MION）的药物载体； [2] 动脉内（I.A.）磁靶向； [3] 具有无与伦比的治疗效力和重复反应机制的大分子药物； [4] 细胞穿透肽介导的细胞药物摄取； [5]将肝素/鱼精蛋白调节的前体药物保护和肿瘤特异性药物重新激活整合到一个单一的药物输送系统中，以克服所有可能的障碍，从而实现一种潜在的无创、磁共振成像引导、临床可行且毒性最小的脑肿瘤药物治疗。通过应用地形优化的 I.A.磁性靶向以避免载体在首次进入循环过程中快速被器官清除，MION 的肿瘤捕获比传统的被动增强渗透性和保留靶向丰富了 350 倍以上。通过采用前药策略，我们在大鼠模型中观察到迄今为止首次实验成功，将微克量的大β-半乳糖苷酶模型蛋白选择性地递送至脑肿瘤，但不递送至同侧或对侧正常脑区域。由于大多数毒素/siRNA药物的治疗方案能够完全（>99.9%）根除处于纳摩尔范围内的肿瘤，因此达到这一阈值的前景实际上是可以实现的。
In this review, we discussed the establishment of a so-called “theranostic“ system by instituting the basic principles including the use of: [1] magnetic iron oxide nanoparticles (MION)-based drug carrier; [2] intra-arterial (I.A.) magnetic targeting; [3] macromolecular drugs with unmatched therapeutic potency and a repetitive reaction mechanism; [4] cell-penetrating peptide-mediated cellular drug uptake; and [5] heparin/protamine-regulated prodrug protection and tumor-specific drug re-activation into one single drug delivery system to overcome all possible obstacles, thereby achieving a potentially non-invasive, magnetic resonance imaging-guided, clinically enabled yet minimally toxic brain tumor drug therapy. By applying a topography-optimized I.A. magnetic targeting to dodge rapid organ clearance of the carrier during its first passage into the circulation, tumor capture of MION was enriched by >350 folds over that by conventional passive enhanced permeability and retention targeting. By adopting the prodrug strategy, we observed by far the first experimental success in a rat model of delivering micro-gram quantity of the large β-galactosidase model protein selectively into a brain tumor but not to the ipsi- or contra-lateral normal brain regions. With the therapeutic regimens of most toxin/siRNA drugs to fully (>99.9%) eradicate a tumor being in the nano-molar range, the prospects of reaching this threshold become practically accomplishable.
登录
查看更多内容
影响因子：
4.9
作者：
Chertok B;Cole AJ;David AE;Yang VC
通讯作者：
Yang VC
DOI：
10.1016/j.jconrel.2011.06.033
发表时间：
2011-11-07
期刊：
Journal of controlled release : official journal of the Controlled Release Society
影响因子：
--
作者：
Chertok B;David AE;Yang VC
通讯作者：
Yang VC
影响因子：
7.5
作者：
Byun, Y;Singh, VK;Yang, VC
通讯作者：
Yang, VC
影响因子：
14
作者：
Chertok, Beata;Moffat, Bradford A.;Yang, Victor C.
通讯作者：
Yang, Victor C.
影响因子：
10.3
作者：
GREIG, NH;RIES, LG;RAPOPORT, SI
通讯作者：
RAPOPORT, SI